OsmanKostekMD· @OncologyMarwarD · X·· 22 小时前评分70
正文 · 机器翻译
🚨 ESMO 2026 | FLAURA2 ctDNA 分析
🔬 早期 EGFRm 清除是预后因素，而非 PFS/OS 获益的预测因素。
✅ 无论早期 ctDNA 清除情况如何，Osimertinib + 化疗均改善了结局。
💡 早期 ctDNA 清除不能为省略化疗提供依据。
#ESMO26
16 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
2719RO按 Rapid oral 1: NSCLC, metastatic 对上
FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)
https://esmocongress.esmo.orgLBA73按 Rapid oral 1: NSCLC, metastatic 对上
PACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line
https://esmocongress.esmo.org来源：OsmanKostekMD · x.com